Posted by Michael Wonder on 20 Nov 2019
French Authorities approve national reimbursement of Orkambi (lumacaftor/ivacaftor) for eligible people ages two and older with cystic fibrosis
20 November 2019 - Vertex Pharmaceuticals today announced that the French Authorities (Comité économique des produits de santé, or CEPS) have approved national reimbursement of Orkambi (lumacaftor/ivacaftor) for people ages two and older with cystic fibrosis who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
Orkambi will be available for all eligible patients once the agreement has been published in the French Official Journal.
